Revenues at Salix Pharmaceuticals jumped 43 percent in the first quarter of this year compared with 2006, and the company met Wall Street expectations with a profit of 6 cents per share.

Salix (NASDAQ: SLXP) reported Tuesday that revenues hit $59.8 million and profits were $2.8 million for the first three months of the year.

The company also increased research and development spending to nearly $22 million, which helped reduce profit. However, Salix had announced plans to step up R&D spending.